Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SPY
4. META
5. ANT
6. JBLU
7. SSD
8. ARTV
9. AAPL
10. INTC

Go back to Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 8c

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

March 4, 2021 7:01 AM EST

Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021 

 On track to report results from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in mid-2021

 Company to discontinue Phase 3 COVID-19 trial (LOSVID) 

Extended cash runway into 4Q 2022; raised $50.6 million in gross proceeds from January 2021 public offering

Conference call scheduled for 8:00 a.m. ET today

CAMBRIDGE, Mass., March 04,... More